Answer
Isavuconazonium sulfate (Cresemba) may increase systemic tacrolimus exposure through isavuconazole’s moderate CYP3A4/5 inhibition, so therapeutic drug monitoring and dose adjustment may be necessary during co-administration.
Sources for this answer
- CRESEMBA 200mg Powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 22Document updated
Sources checked